(R)-2-amino-N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (R)-2-amino-N-(5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl)acetamide
• 英文别名: (2R)-2-amino-N-[5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-yl]propanamide
• 化学式: C₂₁H₂₆F₃N₇O₃
• 分子量: 481.478
• InChiKey: LNNOWCVGKHAPRC-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• [EN] PYRIDINE COMPOUNDS USED AS PI3 KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3 KINASE
  申请人：ZHANG DAWEI

  公开号：WO2014110466A1

  公开（公告）日：2014-07-17

  The present invention is directed to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The present invention discloses compounds of Formulas I and II. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.

  本发明涉及新型吡啶类化合物及其衍生物、药用盐、溶剂合物和水合物。本发明公开了I和II式化合物。本发明的化合物和组合物具有蛋白激酶抑制活性，预计可用于治疗蛋白激酶介导的疾病和症状。
• PYRIDINE COMPOUNDS USED AS PI3 KINASE INHIBITORS
  申请人：ZHANG Dawei

  公开号：US20150353524A1

  公开（公告）日：2015-12-10

  The present invention is directed to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The present invention discloses compounds of Formulas I and II. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.

  本发明涉及新型吡啶、其衍生物、药学上可接受的盐、溶剂和水合物。本发明揭示了公式I和II的化合物。本发明的化合物和组合物具有蛋白激酶抑制活性，并预期可用于治疗蛋白激酶介导的疾病和病状。
• Pyridine compounds used as PI3 kinase inhibitors
  申请人：Zhang Dawei

  公开号：US10173995B2

  公开（公告）日：2019-01-08

  The present invention is directed to novel pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The present invention discloses compounds of Formulas I and II. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.

  本发明涉及新型吡啶及其衍生物、药学上可接受的盐、溶液和水合物。本发明公开了式 I 和式 II 的化合物。本发明的化合物和组合物具有蛋白激酶抑制活性，有望用于治疗蛋白激酶介导的疾病和病症。